When was Zytomed Systems founded?

Zytomed Systems was founded in 1998.

Where is Zytomed Systems located?

Zytomed Systems is headquartered in Berlin, Germany.

Who is the current CEO of Zytomed Systems?

Thomas Dittmer of Zytomed Systems.

How many employees does Zytomed Systems have?

As of Dec 31, 2020, the latest employee count at Zytomed Systems is 35.

Is Zytomed Systems a funded company?

Zytomed Systems is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Zytomed Systems rank among its competitors?

Zytomed Systems ranks 92nd amongst 280 active competitors, of which 16 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Y-Biologics, which secured $25.2M in Aug, 2025.

Who are the top competitors of Zytomed Systems?

Zytomed Systems' top competitors include Sino Biological, Y-Biologics and GenScript. Among them, Y-Biologics secured the most recent funding round in August, 2025.

Zytomed Systems - 2026 Company Profile, Team, Funding & Competitors

Company Details

Provider of antibodies and reagents for immunohistochemistry. The products include a wide range of primary antibodies, polymer-based detection systems, high sensitivity streptavidin and biotin-labeled secondary antibodies, reagents such as buffers, chromogenic substrates, enzymes, and PAP pens, as well as cell control assay kits.

Website: www.zytomed-systems.com/
Social
Email ID: *****@zytomed-systems.de
Phone Number: +49 **********

Key Metrics

Founded Year

1998

Location

Berlin, Germany

Stage

Funding Raised

Investors

ARCHIMED

Ranked

92^nd among 280 active competitors

Employee Count

35 as on Dec 31, 2020

Similar Companies

Sino Biological & 336 more

View Zytomed Systems' full profile

Zytomed Systems is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count
Zytomed Systems GmbH CIN: HRB97352 , Germany, Active		-	35 (As on Dec 31, 2020)
ZytoMax Holding GmbH CIN: HRB229716 , Germany, Active	Sep 03, 2020	-	-
ZytoMax GmbH CIN: HRB230106 , Germany, Active	Nov 12, 2020	-	-

Zytomed Systems is a funded company. Zytomed Systems has 1 institutional investor.

View details of Zytomed Systems's funding rounds and investors

Zytomed Systems' employee count trend

Zytomed Systems has 35 employees as of Dec 20. Here is Zytomed Systems's employee count trend over the years:

Employee count trend for Zytomed Systems

Uncover Zytomed Systems' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Zytomed Systems include Sino Biological, Y-Biologics and GenScript. Here is the list of Top 10 competitors of Zytomed Systems, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Sino Biological 2007, Beijing (China), Series A	Provider of reagents,and kits for clinical research	$29.4M	Qiming Venture Partners, CTS Capital & 1 others	67/100
2nd	Y-Biologics 2007, Daejeon (South Korea), Public	Developer of antibodies for the treatment of multiple diseases	$42.1M	InterVest, IMM Investment & 14 others	56/100
3rd	GenScript 2002, Piscataway (United States), Public	Provider of reagents and instruments for life sciences research	$15M	Kleiner Perkins, Vermögensclub & 1 others	55/100
4th	Shanghai OPM Biosciences 2013, Pudong (China), Series B	Antibody culture media and vaccine culture products developer	$14.4M	CPE, China Life Great Health Fund & 5 others	54/100
5th	Allele Biotech 1999, San Diego (United States), Series B	cGMP iPSCs and cell therapy CDMO accelerating regenerative medicine programs	$18M	NIH, HHS & 1 others	53/100
6th	Mabtech 1986, Nacka (Sweden), Acquired	Develops antibodies and ELISA kits	-	Merieux Equity Partners, IK Partners & 1 others	52/100
7th	Pixelgen Technolgies 2020, Stockholm (Sweden), Series A	Developer of ground-breaking technologies for biomedical research and diagnostics	$6M	Industrifonden, Navigare Ventures & 1 others	52/100
8th	ITBMed 2016, Stockholm (Sweden), Series A	Developer of monoclonal antibodies to prevent transplant rejections	$87M	3E Bioventures Capital, Yonjin Capital & 2 others	51/100
9th	Immuno-Biological Laboratories 1982, Fujioka (Japan), Public	Manufacture antibodies	-	Japan Asia Investment, Hokkaido Venture Capital ... & 3 others	49/100
10th	Antibodies.com 2015, Cambridge (United Kingdom), Seed	Provider of portfolio of diagnostic reagents	$506K	Nidobirds Venture, Torianna Consultants & 8 others	49/100
92nd	Zytomed Systems 1998, Berlin (Germany), Funding Raised	Provider of antibodies and reagents for immunohistochemistry	-	ARCHIMED	27/100